ArticleFrontiers in genetics2018
The Distribution and Outcomes of the 21-Gene Recurrence Score in T1-T2N0 Estrogen Receptor-Positive Breast Cancer With Different Histologic Subtypes.
Article in Frontiers in genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mixed invasive ductal lobular carcinoma is clinically and pathologically more similar to invasive lobular than ductal carcinoma.British journal of cancer · 2023Pooled it
- Clinical Usefulness of a Multigene Testing in Patients with Special Histologic Type Breast Cancer.Yonsei medical journal · 2025Article
- Racial/ethnic differences in 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer.BMC cancer · 2024Observational
- Review
- Response to Maltoni, Puccetti, Poli, et al.Journal of the National Cancer Institute · 2023Article
- Can We Forgo Sentinel Lymph Node Biopsy in Women Aged ≥ 50 Years with Early-Stage Hormone-Receptor-Positive HER2-Negative Special Histologic Subtype Breast Cancer?Annals of surgical oncology · 2023Article
- Association of Neighborhood-Level Household Income With 21-Gene Recurrence Score and Survival Among Patients With Estrogen Receptor-Positive Breast Cancer.JAMA network open · 2023Article
- Breast Cancer with Low Recurrence Score on Oncotype DXOncology and therapy · 2022Article
- The 21-gene recurrence score in early non-ductal breast cancer: a National Cancer Database analysis.NPJ breast cancer · 2022Article
- Oncotype DX 21-gene test has a low recurrence score in both pure and mixed mucinous breast carcinoma.Oncology letters · 2021Article
- Invasive lobular carcinoma of the breast: the increasing importance of this special subtype.Breast cancer research : BCR · 2021Review
- Distribution and influence of the 21-gene recurrence score on chemotherapy decision-making in special type of breast cancer.American journal of cancer research · 2021Article
- Should women with early breast cancer under 40 years of age have a routine 21-gene recurrence score testing: A SEER database study.Breast (Edinburgh, Scotland) · 2020Article
- A Risk Stratification Model for Predicting Overall Survival and Surgical Benefit in Triple-Negative Breast Cancer Patients WithFrontiers in oncology · 2020Article
- Impact of the 21-gene recurrence score assay on chemotherapy decision making and outcomes for breast cancer patients with four or more positive lymph nodes.Annals of translational medicine · 2019Article
- LobSig is a multigene predictor of outcome in invasive lobular carcinoma.NPJ breast cancer · 2019Article
- Tubular Carcinoma of the Breast: The Possibility to Omit Sentinel Lymph Node Biopsy.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.